Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Hongchao Zhen"'
Publikováno v:
Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Background This study aimed to evaluate whether inosine enhances the efficacy of immune‐checkpoint inhibitors in human malignant solid tumors. Methods This single‐center, prospective, randomized, open‐label study was conducted, from Ja
Externí odkaz:
https://doaj.org/article/2a42f36d77c74567a680cf978bc30f38
Autor:
Hongchao Zhen, Jizheng Tian, Guangxin Li, Pengfei Zhao, Ying Zhang, Juanjuan Che, Bangwei Cao
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-15 (2023)
Abstract Background Anlotinib is a multi-targeted receptor tyrosine kinase inhibitor (TKI) which has exhibited encouraging clinical activity in advanced non-small cell lung cancer (NSCLC) and soft tissue sarcoma. Raltitrexed is well known to be effec
Externí odkaz:
https://doaj.org/article/9d0368a2210b4ababf2c4d8cbe0aad45
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-16 (2023)
Abstract Background Radiotherapy resistance is the main cause of low tumor regression for locally advanced rectum adenocarcinoma (READ). The biomarkers correlated to radiotherapy sensitivity and potential molecular mechanisms have not been completely
Externí odkaz:
https://doaj.org/article/5e0cf64cd96649918e222b4aaae1b73b
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-15 (2022)
Abstract Background Postoperative adjuvant cisplatin-based chemotherapy had been the standard care in patients with completely resected high-risk stage IB to IIIA non-small cell lung cancer (NSCLC) for decades. However, the survival benefits were far
Externí odkaz:
https://doaj.org/article/605045d938ec4bb491c5ed1beef92d12
Publikováno v:
Immunity, Inflammation and Disease, Vol 9, Iss 4, Pp 1584-1595 (2021)
Abstract Introduction Programmed death 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitors are proved to be promising and are applied for the treatment of a variety of solid tumors. This retrospective study evaluated the efficacy of PD‐1/PD
Externí odkaz:
https://doaj.org/article/7e67fd62bbea405ca3ca1c424f2c1796
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundWe performed a systematic review and meta-analysis to evaluate the risks of cardiac adverse events in solid tumor patients treated with monotherapy of immune checkpoint inhibitors (ICIs) or combined therapy of ICIs plus chemotherapy.Methods
Externí odkaz:
https://doaj.org/article/9aa6d67da22c428bbf4e04080f7a38e2
Autor:
Liuting Yang, Xiaoyue Jiang, Han Yan, Yingying Li, Hongchao Zhen, Bingmei Chang, Seyed Kariminia, Qin Li
Publikováno v:
BMC Gastroenterology, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background For patients with advanced gastric cancer (AGC), second-line chemotherapy regimen remains controversial. The efficacy and safety of irinotecan-containing doublet treatment and irinotecan monotherapy were compared in this systemati
Externí odkaz:
https://doaj.org/article/8d66b4d211934c8cb0e2f2e29733e9e1
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e104346 (2014)
Gemcitabine (GEM) is the standard first-line chemotherapy that provides limited clinical benefits for patients with locally advanced/metastatic pancreatic adenocarcinoma (LA/MPC). However, the fluorouracil derivatives (CAP and S-1) show promising eff
Externí odkaz:
https://doaj.org/article/d31084dad7864cab9b72f7322dac1207
Publikováno v:
Immunity, Inflammation and Disease, Vol 9, Iss 4, Pp 1584-1595 (2021)
Immunity, Inflammation and Disease
Immunity, Inflammation and Disease
Introduction Programmed death 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitors are proved to be promising and are applied for the treatment of a variety of solid tumors. This retrospective study evaluated the efficacy of PD‐1/PD‐L1 inh
Publikováno v:
J Thorac Dis
BACKGROUND: Discs large homolog 5 (Dlg5) is a newly discovered member of the membrane-associated guanylate kinase superfamily (MAGUK) that is involved in several important processes, including the maintenance of epithelial cell polarity, cell prolife